Tilray, Inc. (NASDAQ: TLRY), a global leader in cannabis research and production, today announced that it partnered with researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney to complete a study examining the effects of cannabis on driving and cognitive function.
“The Effects of Medicinal Cannabinoids on Driving” study was a double blind, placebo-controlled study that compared the effects of two varieties of cannabis – a variety containing high levels of THC and a variety containing a 1:1 balanced ratio of THC:CBD – to a placebo, which contained neither THC nor CBD. Tilray supplied the cannabis varieties for the study from its Good Manufacturing Practices (GMP) certified facility in Nanaimo, British Columbia.
“We studied the extent to which cannabis affects driving and specifically, whether CBD moderates the effects of THC,” says Thomas Arkell, a Lambert Initiative researcher, who oversaw the trial. “The two main objectives of the six-month study were to characterise and understand how vaporized cannabis effects people’s driving and to establish whether there are differences in the effects of cannabis containing either high THC and very little CBD or a 1:1 balanced ratio of THC and CBD”.
The trial phase of this study was completed in 2018 and the published results are expected in 2019.
“We’re proud to support this important research,” says Dr. Catherine Jacobson, Vice President of Regulatory and Medical Affairs for Tilray. “Patient safety is a top priority at Tilray. The research conducted at the University of Sydney will provide solid scientific data on the implications for driving after consuming cannabis that will be an asset for the entire industry.”
Tilray is proud to serve authorised medical cannabis patients in Australia and New Zealand. Prospective patients and interested physicians can contact Tilray at email@example.com or 1800-361-664.
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in twelve countries spanning five continents.